HF foundational therapies were appropriately prescribed with 97% (64/66) taking renin-angiotensin or combined neprilysin inhibitors, 89% (59/66) on beta-blockers, 65% (43/66) on mineralocorticoid antagonists, and 21% (14/66) on sodium-glucose cotransporter-2 inhibitors. The gene discussed is REN; the disease is hydrops fetalis.